Coffee consumption and adverse cardiovascular events in patients with atrial fibrillation.

Autor: Iten V; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Cardiology, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland., Herber E; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Cardiology, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland., Coslovsky M; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Cardiology, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland.; Department Klinische Forschung, University of Basel and University Hospital, Basel, Switzerland., Hennings E; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Cardiology, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland., Paladini RE; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Cardiology, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland., Reichlin T; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Rodondi N; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.; Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland., Müller AS; Department of Cardiology, Triemli Hospital Zurich, Zurich, Switzerland., Stauber A; Department of Cardiology, Triemli Hospital Zurich, Zurich, Switzerland., Beer JH; Department of Medicine, Cantonal Hospital of Baden and Molecular Cardiology, University Hospital of Zurich, Zurich, Switzerland., Brenner R; Department of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland., Conte G; Division of Cardiology, Cardiocentro Ticino Insitute, Ente Ospedaliero Cantonale, Lugano, Switzerland., Kobza R; Department of Cardiology, Kantonsspital Luzern, Luzern, Switzerland., Di Valentino M; Department of Cardiology, Ospedale San Giovanni, Bellinzona, Switzerland., Bedoya PC; Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland., Moradi F; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Cardiology, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland., Sinnecker T; Department of Biomedical Engineering, University of Basel, Medical Image Analysis Center (MIAC AG), Basel, Switzerland., Bonati LH; Department of Neurology and Stroke Center, University Hospital Basel, University of Basel, Basel, Switzerland.; Research Department, Reha Rheinfelden, Rheinfelden, Switzerland., Kühne M; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Cardiology, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland., Osswald S; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Cardiology, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland., Conen D; Population Health Research Institute, McMaster University, Hamilton, Canada., Aeschbacher S; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland. stefanie.aeschbacher@usb.ch.; Department of Cardiology, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland. stefanie.aeschbacher@usb.ch., Zuern CS; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland. christinestefanie.meyer-zuern@usb.ch.; Department of Cardiology, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland. christinestefanie.meyer-zuern@usb.ch.
Jazyk: angličtina
Zdroj: BMC medicine [BMC Med] 2024 Dec 18; Vol. 22 (1), pp. 593. Date of Electronic Publication: 2024 Dec 18.
DOI: 10.1186/s12916-024-03817-x
Abstrakt: Background: There is some evidence of reduced major cardiovascular event (MACE) rates associated with moderate coffee consumption in the general population. However, there is concern about the potential risks of coffee consumption in patients with atrial fibrillation (AF). Therefore, we aimed to investigate the association between coffee consumption and MACE in AF patients.
Methods: Data of patients with documented AF enrolled in two large prospective observational multicenter cohort studies (Swiss-AF and Beat-AF) were analyzed. Follow-up information was obtained on a yearly basis. Coffee consumption was categorized into two main groups: "daily" and "not-daily" coffee consumers as well as additional subcategories. The primary endpoint was MACE, defined as a composite of stroke or systemic embolism, myocardial infarction, hospitalization for acute heart failure, and cardiovascular mortality. Secondary endpoints were the individual components of MACE and all-cause mortality. We performed time-updated multivariable adjusted Cox regression analyses to investigate the association between coffee consumption and MACE.
Results: The incidence rate for MACE was 5.09 per 100 person-years (py) in daily and 7.49 per 100 py in not-daily consumers (median follow-up duration: 4.7 years). After adjustment for pre-selected confounding variables, daily coffee consumption was associated with a 23% lower hazard for MACE compared to not-daily consumption (hazard ratio (HR) (95% confidence interval (CI)) 0.77 (0.66; 0.89)). Patients with moderate coffee consumption (2-3 cups/day) had the lowest hazard for MACE compared to patients with not-daily coffee consumption (HR (95% CI) 0.74 (0.63; 0.87)).
Conclusions: In a population of AF patients, daily coffee consumption was associated with a reduced risk for MACE, hospitalization for acute heart failure, and all-cause mortality. The results were inconclusive for stroke or systemic embolism, myocardial infarction, and cardiovascular death. In this analysis, we found no evidence of an unfavourable association of daily coffee consumption in AF Patients with adverse outcome events.
Trial Registration: ClinicalTrials.gov Identifier: NCT02105844.
Competing Interests: Declarations. Ethics approval and consent to participate: The study protocols were approved by the main ethics committee (Ethikkommission Nordwest- und Zentralschweiz EKNZ) and conducted in accordance with the Helsinki Declaration. Written informed consent to participate in this study was provided by all participants. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje